- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00661466
Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery
A Phase II, Randomized, Single-dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx Bupivacaine Implant in Patients After Gastrointestinal Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gastrointestinal (GI) surgery encompasses a range of surgical procedures that involve abdominal incision. Gastrointestinal surgery may be performed to treat an abdominal aortic aneurysm, ulcerative colitis, Crohn's disease, gallbladder disease, bile duct disease and morbid obesity. Although less invasive laparoscopic procedures are performed when warranted, open abdominal surgery is required for certain indications and for more complicated or advanced cases.
Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes for cow tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery.
This study will compare the amount of narcotic pain medication required after surgery in patients who receive the CollaRx Bupivacaine implant or a plain collagen sponge.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Albany, New York, United States, 12208
- Albany Medical Center Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be a man or woman who is ≥ 18 and ≤ 75 years of age.
- Has a body mass index (BMI) > 19 and < 40 kg/m2.
- Has a planned elective surgery that requires a vertical or transverse abdominal incision (including but not limited to abdominal aortic aneurysm repair, cholecystectomy and simple bowel resection) to be performed according to standard surgical technique under general anesthesia.
- Has a risk classification of I, II or III according to the American Society of Anesthesiologists (ASA)
- If female, is nonpregnant (negative pregnancy test at Screening and Day 0 before surgery) and nonlactating.
- If female, is either not of childbearing potential or practicing a defined medically acceptable method of birth control and agrees to continue with the regimen throughout the study.
- Is free of other physical or mental conditions that, in the opinion of the Investigator, may confound quantification of postoperative pain resulting from the surgery.
- Has the ability and willingness to comply with the study procedures and the use of the pain scales; is deemed capable of operating a PCA device; and is able to communicate meaningfully with the study staff.
- Must voluntarily sign and date an informed consent form (ICF) that is approved by an IRB prior to the conduct of any study specific procedures.
- Must be able to fluently speak and understand English and be able to provide meaningful written informed consent for the study.
Exclusion Criteria:
- Has known hypersensitivity to amide local anesthetics, opioids or bovine products, or to inactive ingredients of the test article.
- Has 1 of the following surgical procedures planned: total abdominal hysterectomy, omentectomy or surgical procedure for staging cancer.
- Requires the use of Seprafilm® or other absorbable adhesion barriers for the GI surgery.
Requires any additional surgical procedures either related or unrelated to the GI surgery during the same hospitalization.
- Is required to receive neuraxial (spinal or epidural) opioid analgesics during the study.
- Has cardiac arrhythmia or atrioventricular (AV) conduction disorders.
- Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).
- Has used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery but are subject to preoperative restrictions for oral intake.
- Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on a stable dose regimen for ≥ 30 days prior to Screening.
- Has undergone another major surgery within 3 months of the GI surgery.
- Has known or suspected history of alcohol or drug abuse or misuse within 3 years of Screening or evidence of tolerance or physical dependency on opioid analgesics or sedative hypnotic medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
|
|
Placebo Comparator: 2
Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Total Amount of Opioid Rescue Analgesia Used
Time Frame: 0 to 24 hours postoperatively
|
Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
0 to 24 hours postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Total Amount of Opioid Rescue Analgesia Used
Time Frame: 0 to 48 hours postoperatively
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
0 to 48 hours postoperatively
|
The Total Amount of Opioid Rescue Analgesia Used
Time Frame: 0 to 72 hours postoperatively
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
0 to 72 hours postoperatively
|
Pain Intensity Rating on the Visual Analogue Scale (VAS)
Time Frame: 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
|
Pain Intensity Rating on a 4-point Scale
Time Frame: At 1, 1.5, 2, 3, 6, 9, 12, 18, 24, 36, 48 and 72 hours postoperatively
|
Study Terminated Early - Secondary end point not measured - not done
|
At 1, 1.5, 2, 3, 6, 9, 12, 18, 24, 36, 48 and 72 hours postoperatively
|
Pain Relief Rating on a 5-point Scale
Time Frame: At 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
At 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
|
Patient Global Evaluation of Study Treatment on a 5-point Scale
Time Frame: At 72 hours after time 0
|
Study Terminated Early - Secondary end point not measured - not done
|
At 72 hours after time 0
|
Time to First Use of Opioid Rescue Analgesia
Time Frame: actual time from time 0
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
actual time from time 0
|
Pharmacokinetic Parameters
Time Frame: 30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48 and 72 hours postoperatively
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
30 minutes, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36, 48 and 72 hours postoperatively
|
The Incidence of Treatment-emergent Adverse Events
Time Frame: Through 30 days after surgery
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
Through 30 days after surgery
|
Changes in Vital Sign Measurements
Time Frame: Through 72 hours post insertion
|
Study Terminated Early - Secondary end point not measured - not done - Study Terminated early due to very poor study enrollment.
Target recruitment not met.
Primary outcome not measured - planned statistical analyses was not performed.
|
Through 72 hours post insertion
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INN-CB-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Postoperative
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States